Notably, silencing MYH9 significantly attenuates ACTN1's tumor-promoting effects, supporting the notion that ACTN1 drives HNSCC tumorigenesis primarily by boosting MYH9-dependent GSK-3β degradation. This evidence concerns the gene ACTN1 and head and neck squamous cell carcinoma.